VivoSeq
Other

Acinetobacter Baumannii

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Acinetobacter Baumannii is an early-stage landscape with 0 programs across 2 companies. The most active players are Entasis Therapeutics, Innoviva Specialty Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Entasis Therapeutics

0 programs

PreclinicalI

Innoviva Specialty Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Unknown status3 · 38%
Completed3 · 38%
Not yet recruiting1 · 13%
Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Recruiting·IInnoviva Specialty Therapeutics·Phase 1·NCT06801223·48 enrolled
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Not yet recruiting·BBioVersys AG·Phase 2·NCT07431307·120 enrolled
Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
Completed·—·N/A·NCT02482961·30 enrolled
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Completed·EEntasis Therapeutics·Phase 3·NCT03894046·207 enrolled
Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii
Completed·GGangnam Severance Hospital·N/A·NCT03622918·9 enrolled
Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
Unknown status·HHospitales Universitarios Virgen del Rocío·Phase 3·NCT00645723·67 enrolled
Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii
Unknown status·MMahidol University·Phase 4·NCT01342731·30 enrolled
Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii
Unknown status·MMahidol University·Phase 3·NCT01297894·92 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)